Get started
NOVO-NORDISK AS B DK 0,1NOVO-NORDISK AS B DK 0,1NOVO-NORDISK AS B DK 0,1

NOVO-NORDISK AS B DK 0,1

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals Bonds

NOV chart


Full chart

Key facts today

Novo Nordisk's CagriSema obesity drug trial results were disappointing, impacting market sentiment and contributing to a decline in Zealand Pharma's share price.
Analyze the impactAnalyze the impact

NOV upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪440.56 B‬ EUR
Dividend yield (indicated)
1.33%
Price to earnings Ratio (TTM)
35.50
Basic EPS (TTM)
2.84 EUR
Net income (FY)
‪11.22 B‬ EUR
Revenue (FY)
‪31.15 B‬ EUR
Shares float
‪3.13 B‬
Beta (1Y)
1.37

Employees


Employees (FY)
‪63.37 K‬
Change (1Y)
‪+8.98 K‬ +16.50%
Revenue / Employee (1Y)
‪491.54 K‬ EUR
Net income / Employee (1Y)
‪177.10 K‬ EUR

About NOVO NORDISK B A/S


Sector
Health Technology
CEO
Lars Fruergaard Jørgensen
Headquarters
Bagsværd
Website
novonordisk.com
Founded
1931
ISIN
DK0062498333
FIGI
BBG000DYN870
Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

NOV news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

NOV highest yielding bonds


N
XS282046075
NOVO NO.F.NL 24/34 MTN
Yield to maturity
3.14%
Maturity date
May 21, 2034
N
XS282045567
NOVO NO.F.NL 24/31 MTN
Yield to maturity
2.86%
Maturity date
Jan 21, 2031
XS244124704
NOVO NO.F.NL 22/30MTN
Yield to maturity
2.77%
Maturity date
Mar 31, 2030
N
XS282045460
NOVO NO.F.NL 24/29 MTN
Yield to maturity
2.73%
Maturity date
Jan 21, 2029
XS234803042
NOVO NO.F.NL 21/28
Yield to maturity
2.73%
Maturity date
Jun 4, 2028
N
XS282044994
NOVO NO.F.NL 24/26 MTN
Yield to maturity
2.69%
Maturity date
May 21, 2026
XS244124453
NOVO NO.F.NL 22/25 MTN
Yield to maturity
2.66%
Maturity date
Mar 31, 2025
XS244933017
NOVO NO.F.NL 22/27MTN
Yield to maturity
2.39%
Maturity date
Sep 30, 2027

Explore more bonds 

Sparks


Curated watchlists where NOV is featured.

See all sparks 

Frequently Asked Questions


The current price of NOV is 82.50 EUR — it has decreased by −18.01% in the past 24 hours. Watch NOVO-NORDISK AS B DK 0,1 stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on FWB exchange NOVO-NORDISK AS B DK 0,1 stocks are traded under the ticker NOV.
NOV stock has fallen by −20.96% compared to the previous week, the month change is a −15.54% fall, over the last year NOVO-NORDISK AS B DK 0,1 has showed a −11.66% decrease.
We've gathered analysts' opinions on NOVO-NORDISK AS B DK 0,1 future price: according to them, NOV price has a max estimate of 153.73 EUR and a min estimate of 74.86 EUR. Watch NOV chart and read a more detailed NOVO-NORDISK AS B DK 0,1 stock forecast: see what analysts think of NOVO-NORDISK AS B DK 0,1 and suggest that you do with its stocks.
NOV reached its all-time high on Jun 26, 2024 with the price of 140.00 EUR, and its all-time low was 13.26 EUR and was reached on Jan 3, 2014. View more price dynamics on NOV chart.
See other stocks reaching their highest and lowest prices.
NOV stock is 32.39% volatile and has beta coefficient of 1.37. Track NOVO-NORDISK AS B DK 0,1 stock price on the chart and check out the list of the most volatile stocks — is NOVO-NORDISK AS B DK 0,1 there?
Today NOVO-NORDISK AS B DK 0,1 has the market capitalization of ‪347.61 B‬, it has decreased by −2.62% over the last week.
Yes, you can track NOVO-NORDISK AS B DK 0,1 financials in yearly and quarterly reports right on TradingView.
NOVO-NORDISK AS B DK 0,1 is going to release the next earnings report on Feb 5, 2025. Keep track of upcoming events with our Earnings Calendar.
NOV earnings for the last quarter are 0.82 EUR per share, whereas the estimation was 0.80 EUR resulting in a 2.03% surprise. The estimated earnings for the next quarter are 0.83 EUR per share. See more details about NOVO-NORDISK AS B DK 0,1 earnings.
NOVO-NORDISK AS B DK 0,1 revenue for the last quarter amounts to ‪9.56 B‬ EUR, despite the estimated figure of ‪9.67 B‬ EUR. In the next quarter, revenue is expected to reach ‪10.81 B‬ EUR.
NOV net income for the last quarter is ‪3.66 B‬ EUR, while the quarter before that showed ‪2.68 B‬ EUR of net income which accounts for 36.42% change. Track more NOVO-NORDISK AS B DK 0,1 financial stats to get the full picture.
NOVO-NORDISK AS B DK 0,1 dividend yield was 1.35% in 2023, and payout ratio reached 50.35%. The year before the numbers were 1.32% and 50.59% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
As of Dec 21, 2024, the company has ‪63.37 K‬ employees. See our rating of the largest employees — is NOVO-NORDISK AS B DK 0,1 on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. NOVO-NORDISK AS B DK 0,1 EBITDA is ‪18.17 B‬ EUR, and current EBITDA margin is 47.96%. See more stats in NOVO-NORDISK AS B DK 0,1 financial statements.
Like other stocks, NOV shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade NOVO-NORDISK AS B DK 0,1 stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So NOVO-NORDISK AS B DK 0,1 technincal analysis shows the strong sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating NOVO-NORDISK AS B DK 0,1 stock shows the sell signal. See more of NOVO-NORDISK AS B DK 0,1 technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.